Mirna Therapeutics, Inc. ("Mirna") announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a. The currently allowed claims describe methods of reducing cancer cell viability by introducing mir-34a into cancerous T-cells or lung, prostate, or skin cancer cells. The patent allowance stems from Mirna's patent application 60/627,171, filed November 2004, which was one of the earliest patent filings describing clinical applications of microRNAs.
Scientists at Mirna have shown that miR34a functions as a key tumor suppressor and affects multiple cancer-related genes and pathways, such as those involved in cell viability, cell senescence and apoptosis. Using transgenic and xenograft models of cancer, scientists at Mirna, as well as leading cancer researchers at academic institutions, have demonstrated that therapeutic candidates featuring the miR-34a sequence significantly inhibit tumor development, tumor growth, and metastasis. Additional studies have shown that the altered expression of miR-34a is important in cancer stem cell development. Three recent peer-reviewed publications by Mirna scientists describe therapeutic opportunities for miR-34a (Wiggins et al, Cancer Res 2010; 70; 5923-30; Liu et al, Nature Medicine 2011; 17; 211-5; Trang et al, Mol Therapy 2011; Mar epub).
"Close to 100 peer-reviewed publications have detailed the involvement of miR-34 in cancer development. We are very excited about the potential of miR-34a based therapies being used either alone or in combination with traditional and/or targeted therapies to enhance cancer patient care," said Paul Lammers, M.D., President and CEO. "This allowance from the USPTO provides further evidence of the critical position that the Company holds in the burgeoning field of miRNA-based therapies."
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients